Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Down - Should You Sell?

Key Points

• Agios Pharmaceuticals (NASDAQ:AGIO) shares experienced a significant decline, opening at $31.45, down from a prior close of $35.00 and last trading at $28.09.
• Analysts have mixed ratings for Agios, with one analyst issuing a sell rating, two holding, and six maintaining a buy rating; the average target price is $56.33.
• In recent insider trading, notable sales included 2,770 shares sold by Tsveta Milanova and 11,914 shares sold by Sarah Gheuens, indicating a decrease in insider ownership.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report)'s share price gapped down prior to trading on Monday . The stock had previously closed at $35.00, but opened at $31.45. Agios Pharmaceuticals shares last traded at $28.09, with a volume of 650,901 shares traded.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Wall Street Zen cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Scotiabank lowered their target price on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a research note on Monday, July 28th. Finally, Bank of America lowered their price objective on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $56.33.

Agios Pharmaceuticals Price Performance

The company has a market capitalization of $2.16 billion, a P/E ratio of 3.38 and a beta of 0.80. The business has a 50-day moving average of $36.07 and a 200-day moving average of $32.66.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The business had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. Sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, Director David Scadden sold 1,400 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, July 10th. The stock was sold at an average price of $40.00, for a total transaction of $56,000.00. Following the completion of the sale, the director owned 17,603 shares of the company's stock, valued at $704,120. The trade was a 7.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Cecilia Jones sold 1,780 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $59,701.20. Following the completion of the transaction, the chief financial officer directly owned 30,049 shares of the company's stock, valued at $1,007,843.46. The trade was a 5.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 46,363 shares of company stock valued at $1,619,654. Insiders own 4.30% of the company's stock.

Institutional Trading of Agios Pharmaceuticals

Large investors have recently made changes to their positions in the company. GAMMA Investing LLC increased its position in shares of Agios Pharmaceuticals by 9,296.6% during the first quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company's stock worth $240,000 after purchasing an additional 8,088 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in Agios Pharmaceuticals by 3.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company's stock valued at $815,000 after buying an additional 795 shares in the last quarter. Northern Trust Corp grew its holdings in Agios Pharmaceuticals by 0.9% in the 4th quarter. Northern Trust Corp now owns 595,480 shares of the biopharmaceutical company's stock valued at $19,567,000 after buying an additional 5,372 shares in the last quarter. Federated Hermes Inc. grew its holdings in Agios Pharmaceuticals by 4.4% in the 4th quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock valued at $450,000 after buying an additional 582 shares in the last quarter. Finally, Norges Bank purchased a new stake in Agios Pharmaceuticals in the 4th quarter valued at $4,768,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.